Publication

Article

BioPharm International

BioPharm International-03-01-2003
Volume16
Issue 3

Inside Washington: The Big Shift

Author(s):

Jill Wechsler

Jill Wechsler FDA explains its plan for moving most biologics under the authority of CDER. But a big question remains: What will the change do to approval times?

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue
Biotech World: India Blossoms
Inside Washington: The Big Shift
Outsourcing Outlook: One-Stop Shops
Qualification of a Chromatographic Column: Why and How to Do It
Guest Editorial: Recruiting Biotech Talent
Survival Strategies: How to Purchase COTS Software

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet
Tariffs & Trade Policy: Results of a Bio/Pharma Peer Survey
How the 15% US-EU Tariff Cap Affects Bio/pharma
Related Content
Woman with pink ribbon on color background. Breast cancer awareness concept | Image Credit: © Pixel-Shot - stock.adobe.com
August 26th 2025

Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan

Patrick Lavery
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
August 26th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
small interfering RNA bound to a messenger RNA, cartoon model with semi-transparent surface. siRNAs are synthetic RNA interference tools used for inducing temporary reduction of mRNA expression. | Image Credit: © petarg - © petarg - stock.adobe.com
August 26th 2025

Hongene Expands exNA Technology Access for RNA Therapeutics Research with New Licensing Deal

Feliza Mirasol
Mastering Antibody-Drug Conjugates
August 26th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Silver Spring, MD, USA - June 25, 2022: Closeup of the FDA sign seen at its headquarters campus in Silver Spring, Maryland. FDA is a federal agency of the Department of Health and Human Services | Image Credit: © Tada Images - stock.adobe.com
August 26th 2025

Novo Receives FDA 483 for Acquired Catalent Site

Christopher Cole
Human eye close-up in black and white. Extended pupil | Image Credit: © Annashou - stock.adobe.com
August 26th 2025

VeonGen’s Stargardt Disease Gene Therapy Gets FDA RMAT Status

Patrick Lavery
© 2025 MJH Life Sciences

All rights reserved.